SCHOTT Pharma debuts world’s first 5.5 ml prefillable staked-needle glass syringe, paving the way for next-generation biologic therapies at home

New large-volume prefillable glass syringe from SCHOTT Pharma facilitates self-injection of biologics at home. Image: SCHOTT Pharma/Oana Szekely

(IN BRIEF) SCHOTT Pharma has launched the industry’s first 5.5 ml prefillable staked-needle glass syringe, expanding its syriQ BioPure® platform to support biologic therapies designed for home administration. The syringe integrates seamlessly with Ypsomed’s YpsoMate® 5.5 ml autoinjector and Datwyler’s plunger systems, ensuring safe, efficient, and stable drug delivery for large-volume biologics. Featuring ultra-low tungsten levels to protect sensitive formulations, the device meets growing demand for patient-centric drug delivery solutions. CEO Andreas Reisse and Ypsomed CBO Ulrike Bauer highlighted the collaboration as a milestone in advancing homecare treatments and accelerating market access for pharmaceutical companies. SCHOTT Pharma will exhibit the new technology at CPHI Frankfurt 2025.

(PRESS RELEASE) MAINZ, 21-Oct-2025 — /EuropaWire/ — SCHOTT Pharma, a global leader in advanced drug containment and delivery systems, has unveiled the first-ever 5.5 ml prefillable staked-needle glass syringe, a major milestone in large-volume drug delivery innovation. Part of the company’s syriQ BioPure® glass syringe platform, the new format is designed to meet the growing need for safe, precise, and patient-friendly administration of complex biologic treatments outside clinical settings. The syringe is fully compatible with Ypsomed’s YpsoMate® 5.5 ml large-volume autoinjector, giving patients the freedom to self-administer therapies conveniently and comfortably at home.

The introduction of this new syringe comes amid a rising global demand for large-volume injectable solutions, driven by advances in biologics and a shift toward home-based treatment models for chronic conditions such as cancer, autoimmune disorders, and neurological diseases. The 5.5 ml syringe provides pharmaceutical manufacturers with a ready-to-use containment solution that combines scalability, device compatibility, and high safety standards — enabling faster development and commercialization of next-generation drugs.

syriQ BioPure® 5.5 ml is compatible with Ypsomed’s YpsoMate® 5.5 autoinjector for convenient and ergonomic injections. Image: SCHOTT Pharma/Oana Szekely

“This expansion of our BioPure® platform marks a turning point in the evolution of large-volume drug delivery,” said Andreas Reisse, CEO of SCHOTT Pharma. “By offering pharma companies reliable, device-ready options for self-administration, we’re helping accelerate the shift toward homecare, where patients can safely receive complex treatments with confidence and comfort.”

Engineered for sensitive biologics, the syringe maintains ultra-low tungsten content to prevent drug interaction and degradation throughout its shelf life. It ensures precise dosing, smooth integration with automated systems, and long-term stability of biologic formulations. In addition to compatibility with Ypsomed’s YpsoMate® 5.5 ml autoinjector, the syringe also works seamlessly with Datwyler’s latest plunger technologies, providing flexibility for a wide range of injectable drugs and delivery devices.

Ulrike Bauer, Chief Business Officer at Ypsomed, praised the collaboration’s impact on advancing patient-friendly technologies:

“By integrating SCHOTT Pharma’s new large-volume syringe into our YpsoMate® 5.5 autoinjector, we’re enabling the next stage of biologic therapy innovation. This partnership strengthens our commitment to delivering advanced, intuitive injection systems that meet both clinical and patient needs while accelerating market readiness for large-volume treatments.”

The new large-volume prefillable staked-needle glass syringes from SCHOTT Pharma are designed to fit a wide range of upcoming large-volume drug delivery systems. Image: SCHOTT Pharma/Oana Szekely

SCHOTT Pharma will showcase the new syringe and its complete range of large-volume containment and delivery solutions at the CPHI tradeshow in Frankfurt am Main, taking place from October 28–30, 2025. The launch reflects the company’s continued drive to enhance patient autonomy, streamline pharmaceutical production, and foster the global transition from intravenous to subcutaneous administration — an evolution that benefits healthcare systems and patients alike.

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. Every minute, more than 25,000 people receive an injection packed in a SCHOTT Pharma product. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,700 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 17 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is majority owned by SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 957 million in the fiscal year 2024. Further information at www.schott-pharma.com

Media Contact:

Lea Kaiser
PR & Communications Manager
+49 (0) 6131 66-2422

SOURCE: SCHOTT Pharma